bpc 157 ulcerative colitis clinical trial results Frontiers Stable gastric pentadecapeptide BPC 157
Description
First, it works through a completely different mechanism than stimulants, thermogenics, or GLP-1 based peptides
A randomised controlled trial published in Clinical Infectious Diseases demonstrated that Thymosin Alpha-1 treatment in severe COVID-19 patients reduced 28-day mortality by 30% compared to standard care alone.17 While this was acute disease, not long COVID, it confirms the biological plausibility of the immune mechanism
Imaging Biol
BPC-157 carries a 2023 FDA Category 2 designation, and both are on the World Anti-Doping Agency prohibited list
Acknowledgments The authors are grateful to Dr
